Caresyntax, a vendor-neutral precision surgery platform, announced raising a total commitment of $180 million through a series C extension and growth debt expansion round.
Investors in the $180 million round include Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund, and ProAssurance Corp. The financing comprises $80M of equity and up to $100M of growth debt facility.
Related: Biomaterial maker 4D Medicine raises £3.4 million in Series A funding
Caresyntax is transforming surgery by implementing a scalable, end-to-end software and AI platform. The platform is medical grade, interoperable and allows the capture and use of novel data and applications to enhance surgical precision and patient safety. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide, delivering automation and actionable insights to hospitals, medical device companies and insurance groups.
Dennis Kogan, Co-Founder and CEO of Caresyntax shared: “Together with our partners and investors, we are working towards deploying precision surgical tools, empowered by data and AI, to improve patient outcomes. This financing is not just an investment in Caresyntax, but an investment in the future of surgery. My gratitude extends to our investors who contribute to and believe in the power of smart data and AI usage in the operating room.”
